- Home
- VCYT
VCYT
Veracyte Inc.
as 12-18-2024 12:44pm EST
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $39.86 | AVG Volume (30 days): | 720.8K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.61 - $46.00 | Next Earning Date: | 11-06-2024 |
| Revenue: | $425,331,000 | Revenue Growth: | 23.95% |
| Revenue Growth (this year): | 25.25% | Revenue Growth (next year): | 10.12% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McGuire Annie | VCYT | SVP, General Counsel | Dec 4 '24 | Sell | $44.02 | 18,699 | $823,178.60 | 72,869 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Dec 2 '24 | Sell | $43.23 | 7,000 | $302,621.90 | 114,037 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Dec 2 '24 | Sell | $43.25 | 1,050 | $45,407.88 | 73,810 | |
| Wygant Jonathan | VCYT | VP, Chief Accounting Officer | Dec 2 '24 | Sell | $43.36 | 956 | $41,452.45 | 40,270 | |
| Wygant Jonathan | VCYT | VP, Chief Accounting Officer | Nov 27 '24 | Sell | $42.89 | 5,032 | $215,833.55 | 40,270 | |
| EASTHAM KARIN | VCYT | Director | Nov 19 '24 | Sell | $37.76 | 14,731 | $564,768.40 | 18,497 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Nov 12 '24 | Sell | $38.34 | 15,275 | $585,663.36 | 114,037 | |
| EPSTEIN ROBERT S | VCYT | Director | Nov 12 '24 | Sell | $38.32 | 15,000 | $574,830.00 | 44,598 | |
| JONES EVAN/ FA | VCYT | Director | Sep 19 '24 | Sell | $35.23 | 5,173 | $182,262.90 | 0 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
The Zacks Analyst Blog Highlights McKesson, Doximity and Veracyte
Zacks
2 days ago
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave
Simply Wall St.
5 days ago
Exploring Three High Growth Tech Stocks In The United States
Simply Wall St.
5 days ago
US Exchange: 3 Stocks That May Be Trading Below Fair Value
Investor's Business Daily
6 days ago
Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer Diagnostics
Insider Monkey
6 days ago
Veracyte (VCYT) Shares Rebounded in Q3
Zacks
6 days ago
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Simply Wall St.
7 days ago
Those who invested in Veracyte (NASDAQ:VCYT) a year ago are up 68%
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.